Hitoshi Sohma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hitoshi Sohma has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Hiroko Ohkawa
Department of Biochemistry (HS, HO, RS) and the Department of Neuropsychiatry (RS, EH, WU, TS), Sapporo Medical University School of Medicine, Sapporo, Japan; and the Department of Occupational Therapy (HO), Sapporo Medical University School of Health Sciences, Japan
7 shared publications- Eri Hashimoto
Department of Neuropsychiatry, School of Medicine, Sapporo Medical University Sapporo, Japan
4 shared publications Rie Sakai
Department of Biochemistry (HS, HO, RS) and the Department of Neuropsychiatry (RS, EH, WU, TS), Sapporo Medical University School of Medicine, Sapporo, Japan; and the Department of Occupational Therapy (HO), Sapporo Medical University School of Health Sciences, Japan
4 shared publications- Toshikazu Saito
Department of Neuropsychiatry, School of Medicine, Sapporo Medical University Sapporo, Japan
4 shared publications Yoshio Kuroki
4 shared publicationsEri Hashimoto
Department of Neuropsychiatry, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications
Latest Publications
- Open Access
- 1 February 2024
- Published by IntechOpen
MFG-E8, A Novel Biomarker for Alzheimer’s Disease and Its Amyloidotic Feature
Biomarker study on dementia has developed and the most reliable fluid markers are amyloid peptide (A), TAU, and phosphorylated TAU detected in cerebrospinal fluid (CSF). We have focused on novel Alzheimers disease (AD) biomarker candidates (annexin A5 and Milk fat globule-EGF factor 8 protein [MFG-E8]), Ca2+ and phospholipid binding properties, which were elevated in the neuronal cell culture medium by A42 treatment. We have previously reported annexin A5 as an AD biomarker. In this chapter, we focused on MFG-E8. An immunohistochemical study using AD mouse model (APP/PS1) brains revealed characteristic distributions of the staining with anti-MFG-E8 antibody. Anti-MFG-E8 antibody staining was detected in the core regions of the anti-A-antibody stained plaques in 20 weeks old and older APP/PS1 mice, while no staining was observed in control (wild mouse) and anti-A-antibody staining was detected outside of it. The volume of the staining was augmented with advancing age. It was further revealed that the MFG-E8 protein changed to amyloidotic features over time from the Congo red spectral peak shift and electron microscopic study in vitro. As the emergence of senile plaque takes a long time, MFG-E8 present in the plaque might be in an amyloidotic form. From these results, MFG-E8 is a novel biomarker candidate for AD.
- 1 February 2024
- Published by IntechOpen
Open AccessMFG-E8, A Novel Biomarker for Alzheimer’s Disease and Its Amyloidotic Feature
Biomarker study on dementia has developed and the most reliable fluid markers are amyloid peptide (A), TAU, and phosphorylated TAU detected in cerebrospinal fluid (CSF). We have focused on novel Alzheimers disease (AD) biomarker candidates (annexin A5 and Milk fat globule-EGF factor 8 protein [MFG-E8]), Ca2+ and phospholipid binding properties, which were elevated in the neuronal cell culture medium by A42 treatment. We have previously reported annexin A5 as an AD biomarker. In this chapter, we focused on MFG-E8. An immunohistochemical study using AD mouse model (APP/PS1) brains revealed characteristic distributions of the staining with anti-MFG-E8 antibody. Anti-MFG-E8 antibody staining was detected in the core regions of the anti-A-antibody stained plaques in 20 weeks old and older APP/PS1 mice, while no staining was observed in control (wild mouse) and anti-A-antibody staining was detected outside of it. The volume of the staining was augmented with advancing age. It was further revealed that the MFG-E8 protein changed to amyloidotic features over time from the Congo red spectral peak shift and electron microscopic study in vitro. As the emergence of senile plaque takes a long time, MFG-E8 present in the plaque might be in an amyloidotic form. From these results, MFG-E8 is a novel biomarker candidate for AD.
- Open Access
- 25 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 6129
Elucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma
Melanogenesis is the biological and biochemical process of melanin and melanosome biosynthesis. Melanin is formed by enzymic reactions of tyrosinase family proteins that convert tyrosine to form brown-black eumelanin and yellow-red pheomelanin within melanosomal compartments in melanocytes, following the cascades of events interacting with a series of autocrine and paracrine signals. Fully melanized melanosomes are delivered to keratinocytes of the skin and hair. The symbiotic relation of a melanocyte and an associated pool of keratinocytes is called epidermal melanin unit (EMU). Microphthalmia-associated transcription factor (MITF) plays a vital role in melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes for promoting melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis. Diseases involving alterations of EMU show various forms of pigmentation phenotypes. This review introduces four major topics of melanogenesis cascade that include (1) melanocyte development and differentiation, (2) melanogenesis and intracellular trafficking for melanosome biosynthesis, (3) melanin pigmentation and pigment-type switching, and (4) development of a novel therapeutic approach for malignant melanoma by elucidation of melanogenesis cascade.
- 25 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 6129
Open AccessElucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma
Melanogenesis is the biological and biochemical process of melanin and melanosome biosynthesis. Melanin is formed by enzymic reactions of tyrosinase family proteins that convert tyrosine to form brown-black eumelanin and yellow-red pheomelanin within melanosomal compartments in melanocytes, following the cascades of events interacting with a series of autocrine and paracrine signals. Fully melanized melanosomes are delivered to keratinocytes of the skin and hair. The symbiotic relation of a melanocyte and an associated pool of keratinocytes is called epidermal melanin unit (EMU). Microphthalmia-associated transcription factor (MITF) plays a vital role in melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes for promoting melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis. Diseases involving alterations of EMU show various forms of pigmentation phenotypes. This review introduces four major topics of melanogenesis cascade that include (1) melanocyte development and differentiation, (2) melanogenesis and intracellular trafficking for melanosome biosynthesis, (3) melanin pigmentation and pigment-type switching, and (4) development of a novel therapeutic approach for malignant melanoma by elucidation of melanogenesis cascade.
- Open Access
- 28 September 2016
- Published by IntechOpen
Plasma Biomarkers in Alzheimer’s Disease
Plasma Biomarkers in Alzheimer’s Disease | InTechOpen, Published on: 2016-09-28. Authors: Hitoshi Sohma and Yasuo Kokai
- 28 September 2016
- Published by IntechOpen
Open AccessPlasma Biomarkers in Alzheimer’s Disease
Plasma Biomarkers in Alzheimer’s Disease | InTechOpen, Published on: 2016-09-28. Authors: Hitoshi Sohma and Yasuo Kokai
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 5, 15
Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies
Background: Alzheimer’s disease (AD) differs from other forms of dementia in its relation to amyloid beta-42. Using a cell culture model we previously identified annexin A5 as an AD biomarker. Plasma level of annexin A5 was significantly higher in AD patients compared to that in control. AD has been identified to share a number of clinical and pathological features with Dementia with Lewy bodies (DLB). The present study was done to examine whether or not plasma annexin A5 is a specific marker for AD, when being compared with the levels of DLB patients. As ApoE gene subtype 4 has been noticed as the probable genetic factor for AD, we also examined and compared ApoE genotype in both AD and DLB. Methods: Blood samples were obtained from 150 patients with AD (aged 77.6 ± 6.5 years), 50 patients of DLB (79.4 ± 5.0) and 279 community-dwelling healthy elderly individuals of comparable age and sex (75.6 ± 8.1). All AD patients met NINCDS-ADRDA criteria and all DLB patients were diagnosed as probable DLB according to the latest consensus diagnostic criteria. Quantification was done using the Chemiluminescent Enzyme Immunoassay Technique using the monoclonal antibodies against annexin A5. DNA genotyping of ApoE was performed by distinguishing unique combinations of Hha1 fragments of PCR-amplified genomic DNA products. Results: The plasma level of annexin A5 was significantly higher in AD patients than in the healthy individuals (control) (P < 0.0001). The plasma annexin A5 level was also significantly higher in DLB patients than in the control group (P < 0.0001). From the ROC curves, the mean areas under the curve were 0.863 and 0.838 for the AD/control and DLB/control, respectively. The rate of ApoE4 carrier status and the frequency of the e4 allele were significantly higher in AD or DLB than in control and there was no significant difference between AD and DLB. Conclusions: These results suggest that both annexin A5 and ApoE4 are common markers for AD and DLB.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 5, 15
Open AccessEvaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies
Background: Alzheimer’s disease (AD) differs from other forms of dementia in its relation to amyloid beta-42. Using a cell culture model we previously identified annexin A5 as an AD biomarker. Plasma level of annexin A5 was significantly higher in AD patients compared to that in control. AD has been identified to share a number of clinical and pathological features with Dementia with Lewy bodies (DLB). The present study was done to examine whether or not plasma annexin A5 is a specific marker for AD, when being compared with the levels of DLB patients. As ApoE gene subtype 4 has been noticed as the probable genetic factor for AD, we also examined and compared ApoE genotype in both AD and DLB. Methods: Blood samples were obtained from 150 patients with AD (aged 77.6 ± 6.5 years), 50 patients of DLB (79.4 ± 5.0) and 279 community-dwelling healthy elderly individuals of comparable age and sex (75.6 ± 8.1). All AD patients met NINCDS-ADRDA criteria and all DLB patients were diagnosed as probable DLB according to the latest consensus diagnostic criteria. Quantification was done using the Chemiluminescent Enzyme Immunoassay Technique using the monoclonal antibodies against annexin A5. DNA genotyping of ApoE was performed by distinguishing unique combinations of Hha1 fragments of PCR-amplified genomic DNA products. Results: The plasma level of annexin A5 was significantly higher in AD patients than in the healthy individuals (control) (P < 0.0001). The plasma annexin A5 level was also significantly higher in DLB patients than in the control group (P < 0.0001). From the ROC curves, the mean areas under the curve were 0.863 and 0.838 for the AD/control and DLB/control, respectively. The rate of ApoE4 carrier status and the frequency of the e4 allele were significantly higher in AD or DLB than in control and there was no significant difference between AD and DLB. Conclusions: These results suggest that both annexin A5 and ApoE4 are common markers for AD and DLB.
- Open Access
- 1 August 2012
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 13 (10) , 831-835
Biomarkers—a pot of gold or a can of worms?
Biomarkers are biological agents used as indicators of biological states. In clinical applications, biomarkers reflect the presence, severity, or progression of disease states. They may also predict risk or responsiveness of a disease to a given treatment. There has been increasingly intense research interest in biomarkers, yet their translation into routine clinical use is lagging. To stimulate communication and cross-fertilization, the 2nd World Congress on Biomarkers & Clinical Research was held in Baltimore, MD, USA in 2011. The symposium covered a broad range of basic and applied biomarker research with the intent to facilitate bench-to-bedside developments. Sessions discussed DNA-based, proteomic, and blood-borne markers. The presentations covered biomarkers for cancer, other various diseases, and toxicological agents. Other topics included biomarker data assimilation, validation, standardization and quality control, as well as molecular imaging and informatics. New high-throughput assays, model systems and emerging technologies give reasons to hope for further rapid progress in the field.
- 1 August 2012
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 13 (10) , 831-835
Open AccessBiomarkers—a pot of gold or a can of worms?
Biomarkers are biological agents used as indicators of biological states. In clinical applications, biomarkers reflect the presence, severity, or progression of disease states. They may also predict risk or responsiveness of a disease to a given treatment. There has been increasingly intense research interest in biomarkers, yet their translation into routine clinical use is lagging. To stimulate communication and cross-fertilization, the 2nd World Congress on Biomarkers & Clinical Research was held in Baltimore, MD, USA in 2011. The symposium covered a broad range of basic and applied biomarker research with the intent to facilitate bench-to-bedside developments. Sessions discussed DNA-based, proteomic, and blood-borne markers. The presentations covered biomarkers for cancer, other various diseases, and toxicological agents. Other topics included biomarker data assimilation, validation, standardization and quality control, as well as molecular imaging and informatics. New high-throughput assays, model systems and emerging technologies give reasons to hope for further rapid progress in the field.
- 1 May 2011
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 16 (3) , 313-320
Activation of glial cells in the spinal cord of a model of lumbar radiculopathy
- 1 May 2011
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 16 (3) , 313-320
Activation of glial cells in the spinal cord of a model of lumbar radiculopathy
- 15 July 2010
- Published by Wiley in Journal of Neuroscience Research
- Vol. 88 (12) , 2682-2692
Investigation of annexin A5 as a biomarker for Alzheimer's disease using neuronal cell culture and mouse model
Alzheimer's disease (AD) differs from other forms of dementia in its relation to amyloid β peptide (Aβ). Aβ, a proteolytic product of amyloid precursor proteins (APP), has a toxic effect on neuronal cells, which involves perturbation of their Ca2+ homeostasis. This effect implies that changes of protein expression in neuronal cells with calcium stress should provide a molecular marker for this disease. In the present study, we used the supernatant from a neuronal cell culture after incubation with or without Aβ and isolated a Ca2+‐dependent acidic phospholipid binding fraction to perform a proteomic study. Several unique proteins were identified after incubation with Aβ. We focused on annexin A5, among these proteins, because it binds both Ca2+ and lipids likely to be involved in calcium homeostasis. Tg2576 transgenic mice (AD model) overexpressing mutant human APP showed a significant increase of annexin A5 in the brain cortex but not in other organs, including liver, kidney, lung, and intestine. In human plasma samples, the level of annexin A5 was significantly increased in a proportion of AD patients compared with a control group (P < 0.0001 in the logistic regression analysis). From the receiver operating characteristic (ROC) curve with plasma annexin A5 concentrations, the mean area under the curve (AUC 0.898) suggests that annexin A5 is a favorable marker for AD.
- 15 July 2010
- Published by Wiley in Journal of Neuroscience Research
- Vol. 88 (12) , 2682-2692
Investigation of annexin A5 as a biomarker for Alzheimer's disease using neuronal cell culture and mouse model
Alzheimer's disease (AD) differs from other forms of dementia in its relation to amyloid β peptide (Aβ). Aβ, a proteolytic product of amyloid precursor proteins (APP), has a toxic effect on neuronal cells, which involves perturbation of their Ca2+ homeostasis. This effect implies that changes of protein expression in neuronal cells with calcium stress should provide a molecular marker for this disease. In the present study, we used the supernatant from a neuronal cell culture after incubation with or without Aβ and isolated a Ca2+‐dependent acidic phospholipid binding fraction to perform a proteomic study. Several unique proteins were identified after incubation with Aβ. We focused on annexin A5, among these proteins, because it binds both Ca2+ and lipids likely to be involved in calcium homeostasis. Tg2576 transgenic mice (AD model) overexpressing mutant human APP showed a significant increase of annexin A5 in the brain cortex but not in other organs, including liver, kidney, lung, and intestine. In human plasma samples, the level of annexin A5 was significantly increased in a proportion of AD patients compared with a control group (P < 0.0001 in the logistic regression analysis). From the receiver operating characteristic (ROC) curve with plasma annexin A5 concentrations, the mean area under the curve (AUC 0.898) suggests that annexin A5 is a favorable marker for AD.
- 1 January 2010
- Published by Springer Nature
- p. 1-12
Encouraging Appreciation of Community Health Care by Consistent Medical Undergraduate Education
- 1 January 2010
- Published by Springer Nature
- p. 1-12
Encouraging Appreciation of Community Health Care by Consistent Medical Undergraduate Education
- 1 January 2006
- Published by Japanese Electrophoresis Society in SEIBUTSU BUTSURI KAGAKU
- Vol. 50 (4) , 231-236
Plasma proteomic analysis using liposome as a biological ligand.
- 1 January 2006
- Published by Japanese Electrophoresis Society in SEIBUTSU BUTSURI KAGAKU
- Vol. 50 (4) , 231-236
Plasma proteomic analysis using liposome as a biological ligand.
- 1 August 2003
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 27 (s1) , 64S-67S
Augmentation of Ethanol‐Induced Cell Damage and Activation of Nuclear Factor‐κB by Annexin IV in Cultured Cells
Background: We previously reported that the amount of annexin IV expression was increased in culture cells by exposure to ethanol. Here, to investigate the physiologic role of annexin IV, we analyzed ethanol‐induced cytotoxicity and nuclear factor (NF)‐κB activity by using annexin IV‐overexpressed cells.Methods: Annexin IV overexpression was performed by transfection of expression vector, in which annexin IV complementary DNA was ligated, to culture cells (rat glioma C6 cells and human neuroblastoma SH‐SY5Y cells). Ethanol‐induced cytotoxicity was assayed by measuring the mitochondrial enzyme (dehydrogenase) activity or trypan blue exclusion. NF‐κB activity was measured by electrophoretic mobility shift assay with a κB‐oligonucleotide probe.Results: Ethanol‐induced cytotoxicity was increased by overexpression of annexin IV in both C6 cells and SH‐SY5Y cells. Annexin IV overexpression augmented ethanol‐induced NF‐κB activation.Conclusions: Ethanol‐induced increase in annexin IV expression might amplify ethanol‐induced cytotoxicity via NF‐κB activation.
- 1 August 2003
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 27 (s1) , 64S-67S
Augmentation of Ethanol‐Induced Cell Damage and Activation of Nuclear Factor‐κB by Annexin IV in Cultured Cells
Background: We previously reported that the amount of annexin IV expression was increased in culture cells by exposure to ethanol. Here, to investigate the physiologic role of annexin IV, we analyzed ethanol‐induced cytotoxicity and nuclear factor (NF)‐κB activity by using annexin IV‐overexpressed cells.Methods: Annexin IV overexpression was performed by transfection of expression vector, in which annexin IV complementary DNA was ligated, to culture cells (rat glioma C6 cells and human neuroblastoma SH‐SY5Y cells). Ethanol‐induced cytotoxicity was assayed by measuring the mitochondrial enzyme (dehydrogenase) activity or trypan blue exclusion. NF‐κB activity was measured by electrophoretic mobility shift assay with a κB‐oligonucleotide probe.Results: Ethanol‐induced cytotoxicity was increased by overexpression of annexin IV in both C6 cells and SH‐SY5Y cells. Annexin IV overexpression augmented ethanol‐induced NF‐κB activation.Conclusions: Ethanol‐induced increase in annexin IV expression might amplify ethanol‐induced cytotoxicity via NF‐κB activation.